Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis

Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the most recent pharmaceutical group for type 2 diabetes (T2D) treatment. Evidence indicates contradictory relationships between sodium-glucose and bladder cancer (BC). Hence, this study aims to investigate relationship SGLT2 BC in patients with T2D. Materials Methods: This is a systematic review meta-analysis based on Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA). International databases including Cochrane, Web of Science, Scopus, PubMed, Google Scholar were conducted searching keywords without time language limitations. The reference stage continued upgrading until November, 2022. Data analysis was performed STATA 14 software. tests P values lower than 0.05 considered statistically significant. Results: four reviewed studies sample size comprising 497 755 individuals indicated impact T2D (OR: 0.68; 95% CI: 0.37, 1.2). effect dapagliflozin, canagliflozin empagliflozin administration incidence among 0.72; 0.39, 1.30), 0.53; 0.23, 1.20), 0.51; 0.20, 1.28), respectively. Conclusion: general conclusion revealed that did not increase risk patients. subgroups also canagliflozin, Registration: has been compiled PRISMA checklist, its protocol registered PROSPERO website (ID=CRD42023389014).